During the BIO-Europe conference in Stockholm, Optimum co-hosted a special reception featuring a fireside chat with Renée Aguiar-Lucander, former CEO of Calliditas, who led the Swedish company since 2017 until recently – taking it from small biotech to its $1.1 billion acquisition. Here, we tell the story of her remarkable seven-year journey with the firm. Novo […]
Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, on Monday announced a $100 million Series B financing led by TCGX with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio, and participation from UniQuest and founding investor Medicxi. London-based Vicebio said funding […]
COPENHAGEN and SINGAPORE. Novo Holdings today announced its investment in Medi Assist, India’s largest health benefits’ administrator. The investment marks Novo Holdings Asia Investments’ fourth investment in HealthTech, a sector subject to robust growth across the APAC region, and the fifth investment in India. Read more…
Novo Ventures senior partner, Naveed Siddiqi, discussed the opportunity in a slumbering IPO market to raise larger funding rounds, in an interview with Unquote.
LONDON, 29 October 2021: Arix Bioscience plc (LSE: ARIX, “Arix”), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company, Aura Biosciences, Inc., (“Aura”), has announced the pricing of its initial public offering of 5,400,000 shares of common stock at a public offering price of […]
